Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure

Timothy J. Vittorio, Ronald Zolty, Michael E. Kasper, Raj M. Khandwalla, David S. Hirsh, Chi Hong Tseng, Ulrich P. Jorde, Kartikya Ahuja

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Dosing equivalency of carvedilol and metoprolol remains a debate. Degree of β1-blockade is best assessed by blunting of the exercise-induced heart rate. Accordingly, the authors have investigated dosing equivalency by examining baseline and peak exercise heart rates and norepinephrine levels in subjects with chronic heart failure treated with carvedilol or metoprolol. Thirty-seven subjects treated with carvedilol (32.9 ± 3.5 mg; n = 23) or metoprolol succinate (XL) (96.4 ± 15.9 mg; n = 14) referred for cardiopulmonary exercise testing were studied prospectively. Carvedilol versus metoprolol XL subjects did not differ with respect to baseline heart rate (73 ± 2 vs 70 ± 3 bpm), or baseline plasma norepinephrine levels (597.5 ± 78.3 vs 602.1 ± 69.6 pg/mL), P = NS. However, despite similar peak exercise norepinephrine levels (2735.8 ± 320.1 vs 2403.1 ± 371.6 pg/mL), heart rate at peak exercise was higher in subjects receiving carvedilol (135 ± 4 bpm) than those receiving metoprolol XL (117 ± 6 bpm), P = 0.02. Similar norepinephrine release and more complete β1-blockade is observed in well-matched subjects with chronic heart failure treated with a mean daily dose of metoprolol XL 96.4 mg compared with carvedilol 32.9 mg.

Original languageEnglish (US)
Pages (from-to)51-57
Number of pages7
JournalJournal of Cardiovascular Pharmacology and Therapeutics
Volume13
Issue number1
DOIs
StatePublished - Mar 2008
Externally publishedYes

Fingerprint

Metoprolol
Norepinephrine
Heart Failure
Heart Rate
carvedilol

Keywords

  • Carvedilol
  • Heart failure
  • Heart rate
  • Metoprolol
  • Neurohormonal
  • Norepinephrine

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure. / Vittorio, Timothy J.; Zolty, Ronald; Kasper, Michael E.; Khandwalla, Raj M.; Hirsh, David S.; Tseng, Chi Hong; Jorde, Ulrich P.; Ahuja, Kartikya.

In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 13, No. 1, 03.2008, p. 51-57.

Research output: Contribution to journalArticle

Vittorio, Timothy J. ; Zolty, Ronald ; Kasper, Michael E. ; Khandwalla, Raj M. ; Hirsh, David S. ; Tseng, Chi Hong ; Jorde, Ulrich P. ; Ahuja, Kartikya. / Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure. In: Journal of Cardiovascular Pharmacology and Therapeutics. 2008 ; Vol. 13, No. 1. pp. 51-57.
@article{01f20f5804d948709e087d499f92f65f,
title = "Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure",
abstract = "Dosing equivalency of carvedilol and metoprolol remains a debate. Degree of β1-blockade is best assessed by blunting of the exercise-induced heart rate. Accordingly, the authors have investigated dosing equivalency by examining baseline and peak exercise heart rates and norepinephrine levels in subjects with chronic heart failure treated with carvedilol or metoprolol. Thirty-seven subjects treated with carvedilol (32.9 ± 3.5 mg; n = 23) or metoprolol succinate (XL) (96.4 ± 15.9 mg; n = 14) referred for cardiopulmonary exercise testing were studied prospectively. Carvedilol versus metoprolol XL subjects did not differ with respect to baseline heart rate (73 ± 2 vs 70 ± 3 bpm), or baseline plasma norepinephrine levels (597.5 ± 78.3 vs 602.1 ± 69.6 pg/mL), P = NS. However, despite similar peak exercise norepinephrine levels (2735.8 ± 320.1 vs 2403.1 ± 371.6 pg/mL), heart rate at peak exercise was higher in subjects receiving carvedilol (135 ± 4 bpm) than those receiving metoprolol XL (117 ± 6 bpm), P = 0.02. Similar norepinephrine release and more complete β1-blockade is observed in well-matched subjects with chronic heart failure treated with a mean daily dose of metoprolol XL 96.4 mg compared with carvedilol 32.9 mg.",
keywords = "Carvedilol, Heart failure, Heart rate, Metoprolol, Neurohormonal, Norepinephrine",
author = "Vittorio, {Timothy J.} and Ronald Zolty and Kasper, {Michael E.} and Khandwalla, {Raj M.} and Hirsh, {David S.} and Tseng, {Chi Hong} and Jorde, {Ulrich P.} and Kartikya Ahuja",
year = "2008",
month = "3",
doi = "10.1177/1074248407312629",
language = "English (US)",
volume = "13",
pages = "51--57",
journal = "Journal of Cardiovascular Pharmacology and Therapeutics",
issn = "1074-2484",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Differential effects of carvedilol and metoprolol succinate on plasma norepinephrine release and peak exercise heart rate in subjects with chronic heart failure

AU - Vittorio, Timothy J.

AU - Zolty, Ronald

AU - Kasper, Michael E.

AU - Khandwalla, Raj M.

AU - Hirsh, David S.

AU - Tseng, Chi Hong

AU - Jorde, Ulrich P.

AU - Ahuja, Kartikya

PY - 2008/3

Y1 - 2008/3

N2 - Dosing equivalency of carvedilol and metoprolol remains a debate. Degree of β1-blockade is best assessed by blunting of the exercise-induced heart rate. Accordingly, the authors have investigated dosing equivalency by examining baseline and peak exercise heart rates and norepinephrine levels in subjects with chronic heart failure treated with carvedilol or metoprolol. Thirty-seven subjects treated with carvedilol (32.9 ± 3.5 mg; n = 23) or metoprolol succinate (XL) (96.4 ± 15.9 mg; n = 14) referred for cardiopulmonary exercise testing were studied prospectively. Carvedilol versus metoprolol XL subjects did not differ with respect to baseline heart rate (73 ± 2 vs 70 ± 3 bpm), or baseline plasma norepinephrine levels (597.5 ± 78.3 vs 602.1 ± 69.6 pg/mL), P = NS. However, despite similar peak exercise norepinephrine levels (2735.8 ± 320.1 vs 2403.1 ± 371.6 pg/mL), heart rate at peak exercise was higher in subjects receiving carvedilol (135 ± 4 bpm) than those receiving metoprolol XL (117 ± 6 bpm), P = 0.02. Similar norepinephrine release and more complete β1-blockade is observed in well-matched subjects with chronic heart failure treated with a mean daily dose of metoprolol XL 96.4 mg compared with carvedilol 32.9 mg.

AB - Dosing equivalency of carvedilol and metoprolol remains a debate. Degree of β1-blockade is best assessed by blunting of the exercise-induced heart rate. Accordingly, the authors have investigated dosing equivalency by examining baseline and peak exercise heart rates and norepinephrine levels in subjects with chronic heart failure treated with carvedilol or metoprolol. Thirty-seven subjects treated with carvedilol (32.9 ± 3.5 mg; n = 23) or metoprolol succinate (XL) (96.4 ± 15.9 mg; n = 14) referred for cardiopulmonary exercise testing were studied prospectively. Carvedilol versus metoprolol XL subjects did not differ with respect to baseline heart rate (73 ± 2 vs 70 ± 3 bpm), or baseline plasma norepinephrine levels (597.5 ± 78.3 vs 602.1 ± 69.6 pg/mL), P = NS. However, despite similar peak exercise norepinephrine levels (2735.8 ± 320.1 vs 2403.1 ± 371.6 pg/mL), heart rate at peak exercise was higher in subjects receiving carvedilol (135 ± 4 bpm) than those receiving metoprolol XL (117 ± 6 bpm), P = 0.02. Similar norepinephrine release and more complete β1-blockade is observed in well-matched subjects with chronic heart failure treated with a mean daily dose of metoprolol XL 96.4 mg compared with carvedilol 32.9 mg.

KW - Carvedilol

KW - Heart failure

KW - Heart rate

KW - Metoprolol

KW - Neurohormonal

KW - Norepinephrine

UR - http://www.scopus.com/inward/record.url?scp=39049107411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049107411&partnerID=8YFLogxK

U2 - 10.1177/1074248407312629

DO - 10.1177/1074248407312629

M3 - Article

C2 - 18287590

AN - SCOPUS:39049107411

VL - 13

SP - 51

EP - 57

JO - Journal of Cardiovascular Pharmacology and Therapeutics

JF - Journal of Cardiovascular Pharmacology and Therapeutics

SN - 1074-2484

IS - 1

ER -